Pimicotinib

German pharmaceutical giant Merck KGaA has agreed to acquire Connecticut-based SpringWorks Therapeutics for $3.9 billion, paying $47 per share in cash, representing a 26% premium over SpringWorks' unaffected 20-day average price.

Regeneron Pharmaceuticals has announced a $3 billion manufacturing agreement with FUJIFILM Diosynth Biotechnologies in North Carolina, nearly doubling its U.S. large-scale manufacturing capacity for biologic medicines.

The FDA has granted approval to vimseltinib (DCC-3014) for treating symptomatic tenosynovial giant cell tumor (TGCT), based on positive Phase 3 MOTION trial results.

Merck KGaA confirms advanced acquisition discussions with SpringWorks Therapeutics, though critical conditions remain unmet and no binding agreement has been reached.

Preliminary Phase 2 results show pimicotinib achieved a 64% overall response rate (ORR) in chronic Graft-versus-Host Disease (cGvHD) patients who had progressed or not responded to prior therapies.